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Letter to the editor
Challenging the promotion of antidepressants for
nonsevere depression
The editorial by Eriksson and Hieronymus promoting antide-
pressants in nonsevere depression is seriously biased and mis-
leading (1).
Firstly, the authors merely adapted, without critical review,
Furukawa et al.’s (2) study of placebo-controlled, double-
blind randomized trials of new generation antidepressants in
Japan. Although Furukawa et al. initially identified 11 trials
for inclusion, sponsoring companies only agreed to provide
access to patient-level data for six. Two of these could not be
included in the primary analysis because the data were only
available through a remote portal. Further, the trials lasted for
only 6-8 weeks and the authors did not report on adverse
effects. Furukawa et al. found that the efficacy of antidepres-
sants was below the level of clinical relevance (1.62 points
[95% Confidence interval, 0.81–2.43] on the Hamilton Depres-
sion Rating Scale (HDRS) at 8 weeks). Eriksson and Hierony-
mus conclude that the impact of baseline severity on
antidepressant response is a myth, while the more important
conclusion is that the only available evidence is from short-
term trials, based on surrogate measures, ignores adverse
effects, and indicates only minimal efficacy of antidepressants.
Secondly, Eriksson and Hieronymus fail to acknowledge
the general limitations of trials such as those included in the
Furukawa et al. analysis. Crucially, these trials measure
antidepressant effectiveness using depression scales that are
frankly inadequate to assess well-being and functional out-
comes. Indeed, only 1 item out of 17 in the HDRS and no
items in the Montgomery-Asberg Depression Rating Scale
measure well-being. Moreover, sexual function, frequently
impaired by antidepressants, is ignored. The trials included in
Furukawa et al. thus provide essentially no information about
quality of life or recovery of function. Cipriani et al. (3), in a
recent meta-analysis of 522 antidepressant trials (n = 116 477),
highlighted that no data were available to quantify global
functioning, acknowledged to be a highly relevant clinical
outcome.
Thirdly, antidepressants as a class deserve high degree of
scrutiny. Recent critical evaluations have exposed how phar-
maceutical industry-sponsored studies have overestimated
benefits and underestimated harms (4–7). This is especially
true considering the potential for serious harms from antide-
pressants compared to psychotherapy. Serious adverse
effects of antidepressants, including suicide, cannot be over-
looked. In 2004, the Food and Drug Administration issued
a black-box warning for all antidepressants indicating an
association with increased suicidality (8, 9). Other serious
adverse effects also exist. There is no evidence that escitalo-
pram or citalopram is superior in terms of efficacy com-
pared to other antidepressants but robust documentation
has existed since 2001 linking them to serious cardiovascular
adverse effects (QT prolongation and deadly torsade de
pointes) (10, 11). Similarly, duloxetine has no efficacy
advantage versus other antidepressants, but has the potential
for life-threatening liver injury and severe skin reactions,
including Stevens–Johnson syndrome (12, 13). Escitalopram
and duloxetine, included in the Furukawa et al. study, fea-
ture in the yearly list of ‘drugs to avoid’ published by the
independent drug bulletin Prescrire International, having
been assessed to be more dangerous than beneficial (14). In
addition, another selective serotonin reuptake inhibitor
included in the Furukawa study, paroxetine, increases the
risk of cardiac anomalies (15), a major concern as there are
more prescriptions for paroxetine than for any other antide-
pressant among women of child bearing age (16) and many
pregnancies are unplanned (45% in the United States in
2011) (17).
Finally, there is justifiable concern about the overdiagnosis
of depression in people’s lived experience, where mood pertur-
bations commonly reflect real life more than medical illness.
Indeed, they are often understandable and temporary reactions
to loss, bereavement, or other stressors. Many depressive pre-
sentations respond to judicious ‘watchful waiting’ (18) and
support. Most episodes of depression that persist are often suc-
cessfully treated with specific psychosocial interventions, nota-
bly cognitive behavioral therapy (CBT), interpersonal
psychotherapy, or behavioral activation. These treatments,
robustly evidence-based in the real-life setting and over the
long term (19, 20), are often preferred by patients(21) and
known to improve self-esteem, agency, and social functioning
(22). Unfortunately, antidepressant treatment is far more likely
to be reimbursed by healthcare systems than are psychosocial
interventions. Given the lack of evidence for the superiority of
antidepressants over the long term, and in light of the harms
they can cause, (23–25) psychosocial interventions remain the
preferred first option for most patients with nonsevere depres-
sion. This is the recommendation of many national guidelines
such as the one from the Canadian Network for Mood and
Anxiety Treatments (26).
In conclusion, available evidence shows only very limited
effectiveness of antidepressants for nonsevere depression. In
light of this, and their potential harms, their routine use for
this indication cannot be justified; the editorial by Eriksson
and Hieronymus thus seriously misrepresents the utility of
antidepressant medication for nonsevere depression.
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